Safety and efficacy of haploidentical hematopoietic stem-cell transplantation followed by post-transplant high-dose cyclophosphamide (RIC)
Phase 1
- Conditions
- hematological malignancy
- Registration Number
- JPRN-UMIN000015694
- Lead Sponsor
- niversity of Tsukuba, Department of Hematology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with anti-HLA antibody 2) Patients with uncontrollable psychological complications 3) Patients with active double cancer 4) Patients with uncontrollable active infection 5) Pregnant women 6) Patients who are judged inappropriate by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method disease-free survival on day 100
- Secondary Outcome Measures
Name Time Method overall survival, nonrelapse mortality, GVHD and relapse.